Status: Not yet recruiting
TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC
This is a single-arm study designed to evaluate the safety and efficacy of TILs combined with third-generation EGFR-TKIs therapy for patients with EGFR-mutant NSCLC resistant to TKI.
Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Tianjin Medical University General HospitalUpdated: Mar 27, 2026
Eligibility criteria
(1) Age 18-75 years, male or female; (2) Patients with a history of surgical res...
(1) Patients with pathological diagnosis of small cell lung cancer components; (...